Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sunitinib continuous daily regimen in advanced renal cell cancer
NCT00338884Phase 2Completed
- Sponsor
- Pfizer
- Start
- Sep 2006
- Primary completion
- Apr 2009
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 2, open-label, single-arm trial of sunitinib in renal cell carcinoma (RCC), sponsored by Pfizer. Primary endpoint: Objective Response Rate at 1 year. Started Sep 2006; status: completed.
02
Drugs
sunitinib
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT00338884.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00338884.